Dendreon Gets Nod For Ch. 11 Liquidation Plan
A Delaware bankruptcy judge on Tuesday blessed Dendreon Corp.'s proposed Chapter 11 plan, allowing the cancer treatment developer to dole out remaining proceeds from its $495 million sale to Valeant Pharmaceuticals...To view the full article, register now.
Already a subscriber? Click here to view full article